CO2021000506A2 - Soluciones de complejos de radionúclidos estables y concentradas - Google Patents

Soluciones de complejos de radionúclidos estables y concentradas

Info

Publication number
CO2021000506A2
CO2021000506A2 CONC2021/0000506A CO2021000506A CO2021000506A2 CO 2021000506 A2 CO2021000506 A2 CO 2021000506A2 CO 2021000506 A CO2021000506 A CO 2021000506A CO 2021000506 A2 CO2021000506 A2 CO 2021000506A2
Authority
CO
Colombia
Prior art keywords
stable
complex solutions
radionuclide complex
pharmaceutical product
concentrated
Prior art date
Application number
CONC2021/0000506A
Other languages
English (en)
Spanish (es)
Inventor
Daniela Chicco
Donato Barbato
Palo Francesco De
Lorenza Fugazza
Maurizio Mariani
Giovanni Tesoriere
Clementina Brambati
Original Assignee
Advanced Accelerator Applications Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2021000506(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2018/055575 external-priority patent/WO2020021310A1/en
Priority claimed from US16/045,484 external-priority patent/US20200030465A1/en
Application filed by Advanced Accelerator Applications Sa filed Critical Advanced Accelerator Applications Sa
Publication of CO2021000506A2 publication Critical patent/CO2021000506A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CONC2021/0000506A 2018-07-25 2021-01-20 Soluciones de complejos de radionúclidos estables y concentradas CO2021000506A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2018/055575 WO2020021310A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
US16/045,484 US20200030465A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
PCT/IB2018/057415 WO2020021322A1 (en) 2018-07-25 2018-09-25 Stable, concentrated radionuclide complex solutions

Publications (1)

Publication Number Publication Date
CO2021000506A2 true CO2021000506A2 (es) 2021-04-19

Family

ID=63794577

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0000506A CO2021000506A2 (es) 2018-07-25 2021-01-20 Soluciones de complejos de radionúclidos estables y concentradas

Country Status (23)

Country Link
EP (7) EP4545100B1 (cg-RX-API-DMAC7.html)
JP (3) JP7402218B2 (cg-RX-API-DMAC7.html)
KR (4) KR102865113B1 (cg-RX-API-DMAC7.html)
CN (5) CN112584875A (cg-RX-API-DMAC7.html)
AU (7) AU2018433575B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001148A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153630A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000506A2 (cg-RX-API-DMAC7.html)
DE (3) DE202018007006U1 (cg-RX-API-DMAC7.html)
DK (7) DK4640241T3 (cg-RX-API-DMAC7.html)
ES (6) ES3064434T3 (cg-RX-API-DMAC7.html)
FI (7) FI4545101T3 (cg-RX-API-DMAC7.html)
HR (6) HRP20260222T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072720T2 (cg-RX-API-DMAC7.html)
IL (5) IL280314B1 (cg-RX-API-DMAC7.html)
LT (7) LT4541381T (cg-RX-API-DMAC7.html)
MX (2) MX2021000805A (cg-RX-API-DMAC7.html)
PL (6) PL4545100T3 (cg-RX-API-DMAC7.html)
PT (7) PT4541381T (cg-RX-API-DMAC7.html)
RS (7) RS67729B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100645XA (cg-RX-API-DMAC7.html)
SI (6) SI4541381T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020021322A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
US20250032652A1 (en) * 2021-11-30 2025-01-30 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CA3235923A1 (en) * 2022-02-04 2023-08-10 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
US20260102526A1 (en) * 2024-06-27 2026-04-16 Curium Us Llc 177lutetium-dota-tate formulations
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CN100418585C (zh) 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
WO2018081860A1 (en) * 2016-11-04 2018-05-11 Clarity Pharmaceuticals Pty Ltd Formulations for radiotherapy and diagnostic imaging
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Also Published As

Publication number Publication date
FI4541381T3 (fi) 2026-04-01
PT4545100T (pt) 2026-02-16
PL4541380T3 (pl) 2026-03-30
AU2022203683B2 (en) 2023-12-21
LT4541379T (lt) 2026-02-10
RS67667B1 (sr) 2026-02-27
ES3065583T3 (en) 2026-05-06
DK4545100T3 (da) 2026-02-23
EP4541380A3 (en) 2025-07-23
RS67755B1 (sr) 2026-03-31
EP4545100B1 (en) 2025-12-10
ES3064434T3 (en) 2026-04-24
ES3064589T3 (en) 2026-04-27
AU2025220852A1 (en) 2025-09-11
DK4545101T3 (da) 2026-03-02
IL280314A (en) 2021-03-25
DE202018007007U1 (de) 2025-11-13
KR20210035855A (ko) 2021-04-01
FI3826686T3 (fi) 2025-08-20
AU2026204487A1 (en) 2026-07-02
AU2025220852B2 (en) 2025-10-23
EP4541379B1 (en) 2025-11-19
WO2020021322A1 (en) 2020-01-30
CN121081692A (zh) 2025-12-09
EP4545101B1 (en) 2025-12-10
DK4541379T3 (da) 2026-02-02
IL319542A (en) 2025-05-01
IL326944A (en) 2026-05-01
LT4545101T (lt) 2026-03-10
RS68308B1 (en) 2026-07-31
JP2025111424A (ja) 2025-07-30
PT4640241T (pt) 2026-07-17
LT3826686T (lt) 2025-08-25
RS67754B1 (sr) 2026-03-31
FI4545101T3 (fi) 2026-02-24
MX2021000805A (es) 2021-05-12
HRP20260237T1 (hr) 2026-04-10
DK3826686T3 (da) 2025-08-25
EP4640241B1 (en) 2026-06-03
HRP20260179T1 (hr) 2026-04-10
EP4541380A2 (en) 2025-04-23
ES3067415T3 (en) 2026-05-21
CN120860272A (zh) 2025-10-31
EP4640241A2 (en) 2025-10-29
AU2022203683A1 (en) 2022-06-16
LT4541381T (lt) 2026-03-25
PT3826686T (pt) 2025-08-04
IL319542B2 (en) 2026-08-01
EP4545100A2 (en) 2025-04-30
PL4541379T3 (pl) 2026-03-23
DK4541381T3 (da) 2026-04-07
SG11202100645XA (en) 2021-02-25
KR102865113B1 (ko) 2025-09-26
DE202018007006U1 (de) 2025-11-13
FI4541379T3 (fi) 2026-02-17
JP2023117417A (ja) 2023-08-23
SI4541380T1 (sl) 2026-04-30
IL319542B1 (en) 2026-04-01
BR112021001148A2 (pt) 2021-04-20
EP3826686B1 (en) 2025-05-21
HRP20260338T1 (hr) 2026-04-10
EP4541379A2 (en) 2025-04-23
CN120860270A (zh) 2025-10-31
IL319541B1 (en) 2025-09-01
PL4541381T3 (pl) 2026-05-11
SI4545101T1 (sl) 2026-04-30
IL280314B1 (en) 2026-07-01
JP2022501313A (ja) 2022-01-06
KR20250017751A (ko) 2025-02-04
KR102932818B1 (ko) 2026-03-03
SI4541379T1 (sl) 2026-03-31
EP4640241A3 (en) 2025-12-10
AU2025204901A1 (en) 2025-07-17
AU2025202231B2 (en) 2026-05-14
MX2025012060A (es) 2025-11-03
FI4541380T3 (fi) 2026-03-02
PL3826686T3 (pl) 2025-09-22
ES3038413T3 (en) 2025-10-13
EP4541380B1 (en) 2025-12-10
EP4541381A3 (en) 2025-07-23
KR20240033296A (ko) 2024-03-12
PT4541381T (pt) 2026-03-17
EP4541379A3 (en) 2025-07-23
KR102643582B1 (ko) 2024-03-05
EP4541381B1 (en) 2026-02-04
IL313560A (en) 2024-08-01
DK4640241T3 (da) 2026-07-27
IL319541A (en) 2025-05-01
AU2024201217B2 (en) 2025-02-27
FI4640241T3 (fi) 2026-07-21
HRP20250912T1 (hr) 2025-09-26
PT4545101T (pt) 2026-02-24
IL319541B2 (en) 2026-01-01
PT4541380T (pt) 2026-02-24
HUE072720T2 (hu) 2025-12-28
AU2018433575B2 (en) 2022-07-07
CA3153630A1 (en) 2020-01-30
AU2025202231A1 (en) 2025-04-17
EP4541381A2 (en) 2025-04-23
SI3826686T1 (sl) 2025-09-30
EP4545101A3 (en) 2025-07-23
IL313560B1 (en) 2025-07-01
AU2024201217A1 (en) 2024-03-14
CN120860271A (zh) 2025-10-31
PL4545101T3 (pl) 2026-03-30
AU2018433575A1 (en) 2021-02-11
EP3826686A1 (en) 2021-06-02
EP4545100A3 (en) 2025-07-23
HRP20260100T1 (hr) 2026-04-10
LT4640241T (lt) 2026-07-27
DK4541380T3 (da) 2026-02-23
HRP20260222T1 (hr) 2026-03-27
LT4545100T (lt) 2026-02-25
DE202018006567U1 (de) 2021-04-01
CN112584875A (zh) 2021-03-30
PT4541379T (pt) 2026-01-29
PL4545100T3 (pl) 2026-03-30
KR20260030955A (ko) 2026-03-06
FI4545100T3 (fi) 2026-03-02
SI4541381T1 (sl) 2026-05-29
JP7796696B2 (ja) 2026-01-09
RS67729B1 (sr) 2026-03-31
LT4541380T (lt) 2026-03-10
EP4545101A2 (en) 2025-04-30
JP7402218B2 (ja) 2023-12-20
IL313560B2 (en) 2025-11-01
RS67864B1 (sr) 2026-04-30
SI4545100T1 (sl) 2026-03-31
AU2025204901B2 (en) 2025-09-18
RS67034B1 (sr) 2025-08-29
ES3063402T3 (en) 2026-04-16

Similar Documents

Publication Publication Date Title
MX2025012060A (es) Soluciones de complejos de radionuclidos estables y concentradas
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2018014758A (es) Piridinas sustituidas con heteroarilo y metodos de uso.
BR112017005938A2 (pt) compostos, processo de preparação de composto, processo de preparação de conjugado de galnac e ácido nucleico e usos de composto
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
AR105712A1 (es) Composiciones de insulina de rápida acción
AR119655A1 (es) Soluciones de complejos de radionúclidos estables y concentradas
DOP2016000210A (es) Proceso para producir una solución inyectable de noradrenalina de baja concentración, estable
MX2019002781A (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral.
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
BR112018013033A2 (pt) compostos de indolinonas e seu uso no tratamentod de doenças fibróticas
EA201792256A1 (ru) Соли и пролекарства 1-метил-d-триптофана
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
MX2015005038A (es) Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
BR112017016333A2 (pt) compostos anticâncer
MX2018009542A (es) Tratamiento y diagnostico de trastornos inflamatorios.
MX2017008330A (es) Productos para el suministro de compuestos de diagnóstico/terapeuticos al corazon.
MX390841B (es) Preparacion liquida parenteral que comprende compuesto de carbamato.
CO2017003313A2 (es) Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso del mismo en com-posiciones farmacéuticas
MX2014013566A (es) Terapia genica para tratar la hiperamonemia en la encefalopatia hepatica y en otras enfermedades del higado.